FLXN News
Archived Headlines
- Health IPOs down 1% and housing IPOs trade up after heavy discount 02/13/14
- Flexion Therapeutics prices IPO at $13 midpoint 02/11/14
- 9 US IPOs planned for the week of Feb 10 02/10/14
- US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
- Pain biotech Flexion Therapeutics sets terms for $65 million IPO 01/29/14
See more
No pain, more gains: Axsome Therapeutics files for a $58 million IPO
Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. The company cites 2015 IPOs Carbylan Therapeutics...read more
Orphan disease biotech Versartis upsizes IPO and increases range to $19 to $21
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more
Orphan disease biotech Versartis sets terms for $81 million IPO
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $81 million by offering 4.6 million shares at a price range of $16 to $19. At the...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more